Cash, cash equivalents and investments were $1.43B as of September 30, compared to $957.9M as of December 31, 2022. “Vaxcyte has continued to make significant strides toward our goal of building a best-in-class PCV franchise, including VAX-24 and VAX-31, with the intent of delivering the broadest-spectrum of coverage against invasive pneumococcal disease,” said Grant Pickering, CEO and co-founder of Vaxcyte. “Following the positive results from the VAX-24 adult Phase 2 clinical studies, we are pleased to have completed a successful End-of-Phase 2 meeting with the FDA focused on the clinical design of our Phase 3 program. We look forward to continued interactions with regulators through the first quarter of next year to finalize the CMC-related licensure requirements as we prepare to initiate the VAX-24 adult Phase 3 program, with topline data from the pivotal, non-inferiority study expected in 2025.”
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
See today’s best-performing stocks on TipRanks >>
Read More on PCVX:
- Vaxcyte Reports Third Quarter 2023 Financial Results and Provides Business Update
- Vaxcyte to Present at Upcoming Investor Conferences
- Vaxcyte Announces FDA Clearance of Investigational New Drug Application for VAX-31 for the Prevention of Invasive Pneumococcal Disease in Adults
- Vaxcyte receives FDA clearance of IND application for VAX-31
- Vaxcyte, Lonza expand collaboration for PCV manufacturing